3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
申请人:Oncotyrol Center for Personalized Cancer Medicine GMBH
公开号:US11091490B2
公开(公告)日:2021-08-17
The present invention relates to 3-amino-pyrazolo[3,4-d]pyrimidin-4-ones, such as for example, N-4-[1-(2,6-dichloro-4-sulfamoyl-phenyl)-3-dimethylamino-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl]-phenyl}-2-diethylamino-acetamide, particularly useful as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxis and/or treatment of cancer and other proliferative diseases. Furthermore, the present invention relates to processes for the synthesis of said 3-aminopyrazolo[3,4d]pyrimidin-4-ones and intermediates to be used in the processes of the present invention.
本发明涉及 3-氨基吡唑并[3,4-d]嘧啶-4-酮,例如 N-4-[1-(2,6-二氯-4-氨基磺酰基苯基)-3-二甲氨基-4-氧代-4,5-二氢-1H-吡唑并[3,4-d]嘧啶-6-基甲基]-苯基}-2-二乙氨基乙酰胺、特别是作为细胞周期蛋白依赖性激酶(CDK)抑制剂的用途、包含这些成分的药物组合物及其在预防和/或治疗癌症和其他增殖性疾病中的用途。此外,本发明还涉及合成所述 3-氨基吡唑并[3,4d]嘧啶-4-酮的工艺以及用于本发明工艺的中间体。